Swedish Orphan Biovitrum AB: Zynlonta (loncastuximab tesirin

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Sobi and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta

Related Keywords

Norway , Iceland , United States , New Jersey , Stockholm , Sweden , United Kingdom , Liechtenstein , Switzerland , London , City Of , America , Swedish , Lausanne Biop , Anders Ullman , Prnewswire Sobi , Linkedin , Company On Twitter , European Commission , Drug Administration , Sobi Investor Relations Team , Youtube , Committee For Orphan Medicinal Products , European Union , Head Of Research Development , Medicinal Products , Human Use , European Medicines Agency , Medical Affairs , Chief Medical Officer , Ameet Mallik , Chief Executive Officer , Orphan Medicinal Products , San Francisco Bay Area , Cancer Research United Kingdom , North America , Middle East , Sobi Media , Orphan , Iovitrum , Zynlonta , Loncastuximab , Esirine , Approved , Treatment , Relapsed , Refractory , Diffuse , Barge , Fell , Lymphoma ,